Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ocrelizumab effective, safe in relapsing-remitting MS patients

Key clinical point: Ocrelizumab is effective and safe in patients with relapsing-remitting multiple sclerosis who had inadequate responses to previous disease-modifying treatments.

Major finding: The adjusted annualized relapse rate in this cohort was 0.065 with 48 weeks of follow-up.

Study details: A phase 3B study including 608 patients with relapsing-remitting multiple sclerosis who had inadequate response to disease-modifying treatment.

Disclosures: Dr. Leist reported disclosures related to Alkermes, Bayer, Biogen, EMD Serono, Genentech, Inc., Novartis, Sanofi Genzyme, Sun Pharma, and Teva Neuroscience.

Citation:

Leist TP, et al. Presented at the 2019 American Academy of Neurology (AAN) Annual Meeting, May 4-10, 2019. Philadelphia. Presentation S56.007.